Journal article
Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies
KM Field, JT Jordan, PY Wen, MA Rosenthal, DA Reardon
Cancer | Published : 2015
DOI: 10.1002/cncr.28935
Abstract
Anti-angiogenic therapy for glioblastoma has been in the spotlight for several years, as researchers and clinicians strive to find agents with meaningful efficacy against glioblastoma. Bevacizumab in particular, in the second half of the last decade, became the most significant breakthrough in anti-glioblastoma therapy since temozolomide. Optimism for bevacizumab has been somewhat challenged given recent clinical trials that have raised questions regarding its clinical effectiveness, the optimal timing of its use and the validity of endpoints, among other issues. In addition, uncertainty has recently arisen regarding the effects of bevacizumab on quality of life and neurocognitive function, ..
View full abstractGrants
Funding Acknowledgements
Dr. Field received conference travel grants from Roche and Merck Sharp and Dohme and has received Speaker's honoraria from Roche and acted as Principal Investigator of a clinical trial funded by Roche (Roche was not a sponsor of the trial) for work performed outside of the current study. Dr. Wen received research support from Genentech for work performed as part of the current study and is a member of the Roche Advisory Board. Dr. Rosenthal has received honoraria from Roche as a member of the Roche Advisory Board. Dr. Reardon is a member of the Roche Advisory Board and has received personal fees from Genentech/Roche, EMD Serono, Merck/Schering, Novartis, and Amgen for work performed outside of the current study.